Logo of Proteomics International Laboratories (ASX:PIQ)Latest Proteomics International Laboratories (ASX:PIQ) News

Page 1
Page 1 of 5

Market Wrap - Week 45 (2 Nov -> 6 Nov) 2026

NEXTDC, Vintage Energy and Embelton recorded the week’s biggest moves, but each came with a different reason and level of risk.
Across resources, takeovers and healthcare, investors rewarded firm deals while selling companies that still need cash or approvals.
Logan Eniac
7 Nov 2026

Healthcare Wrap - Week 45 (2 Nov -> 6 Nov) 2026

Healthcare shares delivered a mixed week as investors rewarded reimbursement and regulatory progress but punished cash calls and dilution. Noxopharm, Pacific Edge and Mayne Pharma led the largest moves, while several companies still face long waits before sales can grow.
Logan Eniac
7 Nov 2026

Proteomics International seeks A$5 million to fund its next commercial push

Proteomics International has launched a discounted A$5 million share purchase plan as it moves from product development into commercial rollout. Eligible shareholders can buy shares at A$0.10 and may receive a free attaching option, subject to approval.
Ada Torres
2 Nov 2026

Healthcare Wrap - Week 44 (26 Oct -> 30 Oct) 2026

Healthcare shares split between clinical progress and cash pressure this week. Mesoblast rose on stronger Ryoncil sales, while several small biotechnology companies fell as investors weighed funding needs and delayed milestones.
Logan Eniac
31 Oct 2026

Proteomics International takes Promarker nationwide as cash runway remains tight

Proteomics International has begun the national rollout of its Promarker D and Promarker Eso blood tests through Healius, while a A$2 million tax incentive receipt has lifted pro forma cash to A$3.8 million. Promarker Endo also cleared an independent Oxford validation hurdle, but its commercial launch remains conditional.
Ada Torres
30 Oct 2026

Proteomics International sets national launch for Promarker blood tests

Proteomics International will take Promarker D and Promarker Eso nationwide through Healius from 26 October, extending its first commercial release beyond Western Australia and the Northern Territory. The tests will initially be offered privately at $495 and $997, while revenue remains too uncertain to forecast.
Victor Sage
23 Oct 2026

Healthcare Wrap - Week 38 (14 Sept -> 18 Sept) 2026

AdAlta led the healthcare board after a US cell-therapy manufacturing deal gave its automation platform commercial credibility, while Vectus fell despite reporting a profit. Clinical trial updates, diagnostic launches and fresh funding plans kept the sector active.
Logan Eniac
19 Sept 2026

Proteomics International Opens Promarker Tests to Patients in First Commercial Rollout

Proteomics International has begun a controlled release of two Promarker diagnostic tests through Healius in Western Australia and the Northern Territory. National commercial sales are targeted for Q2 FY27, but uptake and revenue remain difficult to estimate at this early stage.
Ada Torres
14 Sept 2026

Healthcare Wrap - Week 33 (10 Aug -> 14 Aug) 2026

Healthcare shares delivered mixed results as Percheron surged on a leadership change, while ResMed gained on stronger sales and portfolio changes.
Biotech funding, medical-device expansion and new software contracts shaped the week, but several small-cap gaps quickly lost ground.
Logan Eniac
15 Aug 2026

Proteomics International Secures Australian Patent for PromarkerEndo Diagnostic Test

Proteomics International has achieved a key patent acceptance in Australia for its PromarkerEndo blood test, reinforcing its intellectual property portfolio and commercialisation strategy in a major healthcare market.
Ada Torres
13 Aug 2026

Healthcare Wrap - Week 31 (27 July -> 31 July) 2026

Xenitra led the healthcare board after a three-year Chinese pharmaceutical deal, while Artrya and InteliCare delivered the week’s biggest contrasting moves. Across the sector, companies raised cash, won regulatory support and pushed deeper into US hospitals and clinics.
Logan Eniac
1 Aug 2026

Proteomics International Advances Commercial Pivot with Healius Deal and US Patent

Proteomics International Laboratories has streamlined operations, secured a key US patent for its endometriosis test, and inked a three-year exclusive distribution deal with Healius for its Promarker diagnostics in Australia.
Ada Torres
27 July 2026